Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vical Joins Forces With Astellas On CMV Vaccine

This article was originally published in PharmAsia News

Executive Summary

Vaccine-focused biotech Vical Inc. announced July 14 that it has inked a global licensing agreement with Japan's Astellas Pharma Inc. to develop and commercialize the biotech's cytomegalovirus (CMV) vaccine, TransVax

You may also be interested in...



Astellas Steps Tentatively Into Global Vaccines, Following Path Of Japanese Competitors

Astellas Pharma is making forays into the vaccines segment, with the support of development firm ClearPath Development Company to accelerate the process.

Astellas Steps Tentatively Into Global Vaccines, Following Path Of Japanese Competitors

Astellas Pharma Inc. is making forays into the vaccines segment, with the support of development firm ClearPath Development Company to accelerate the process.

Deals Of The Week: Merck/Simcere, Pfizer/Hisun, MedImmune/WuXi

The growing importance of emerging markets will be a primary discussion point Sept. 17-19 at Elsevier’s Pharmaceutical Strategic Alliances conference in New York

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC078522

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel